Table 1.
Direct-acting antivirals (DDAs) approved for HCV treatment or investigated in clinical trials (updated in September 2016).
| Class | Generation | Approved substances (developing company) | Substances currently tested in clinical trials (developing company) [phase of development] |
|---|---|---|---|
| NS3/4A protease inhibitors | First generation | Telaprevir (Janssen, Mitsubishi) Boceprevir (Merck) Simeprevir (Janssen) Paritaprevir (AbbVie) Asunaprevir (Bristol-Myers Squibb) Vaniprevir (Merck) |
|
| Second generation | Grazoprevir (Merck) | ABT-493 (AbbVie) [Phase 3] GS-9857 (Gilead Sciences) [Phase 3] |
|
|
| |||
| NS5A inhibitors | First generation | Daclatasvir (Bristol-Myers Squibb) Ledipasvir (Gilead Sciences) Ombitasvir (AbbVie) Elbasvir (Merck) Velpatasvir (Gilead Sciences) |
Odalasvir (Janssen) [Phase 2] Ravidasvir (Presidio) [Phase 2/3] |
| Second generation | ABT-530 (AbbVie) [Phase 3] MK-8408 (Merck) [Phase 2] |
||
|
| |||
| Nucleotide analogue inhibitors of NS5B RNA-dependent RNA polymerase | First generation | Sofosbuvir (Gilead Sciences) | MK-3682 (Merck) [Phase 2] AL-335 (Janssen) [Phase 2] |
|
| |||
| Nonnucleoside inhibitors of NS5B RNA-dependent RNA polymerase | Palm-1 inhibitors | Dasabuvir (AbbVie) | |